One-hour coronavirus triage test developed by SQI Diagnostics to receive funding from University Health Network

Grant of $1 million used to finalize development and deployment of existing assay to triage coronavirus patients

TORONTO, March 24, 2020 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics ("SQI"), has been selected by University Health Network ("UHN") investigators to utilize a previously developed SQI assay to assist clinicians in the triaging of patients with COVID-19, the disease caused by the 2019 novel coronavirus (SARS-CoV-2), as well as other forms of respiratory distress. SQI will receive a portion of the almost $1 million grant awarded to UHN by the Canadian Institutes of Health Research (CIHR) to fund the validation and testing of this novel assay, known as Rapid Acute Lung Injury Diagnostic, or "RALI-Dx™."

RALI-Dx, comprised of several biomarkers indicative of acute lung injury, is being studied to determine its ability to accurately predict whether or not a patient experiencing acute respiratory distress caused by COVID-19 or other underlying cause, can be treated and released for self-monitored home care, admitted to a standard hospital unit, or is likely to develop severe life-threatening symptoms requiring immediate intensive care unit (ICU) admittance and advanced respiratory care measures. The test, performed in less than one hour, brings a new level of care that can be deployed in order to triage patients in the currently expanding global coronavirus pandemic.

According to the American Hospital Association, there are only 46,000 total ICU beds in the United States and demand is said to potentially reach as many as 200,000. It is also estimated that almost one million Americans could require mechanical breathing intervention with the use of ventilator machines. However, according to a paper printed in the Society of Critical Care Medicine, the American healthcare system can only support this need for 135,000 people. The one-hour RALI-Dx test will allow physicians to properly allocate these resources.

With COVID-19 now a global healthcare crisis, the availability of critical resources such as ICU beds and ventilator machines are quickly becoming more endangered. With a current gap in the ability to objectively identify who requires admission to intensive care vs. who can be safely monitored at-home, hospitals are already facing significant pressure in triaging patients in respiratory distress. RALI-Dx is ideally positioned to fill this need and serve as an indispensable tool to manage limited critical resources in a historic time of need.

"Joining the global fight against COVID-19 presents a tremendous opportunity for SQI," said Eric Brouwer, PhD, interim CEO of SQI. "Not only is it an opportunity to allow our organization to commercialize an assay we have already developed, but it is also an opportunity to make a positive impact for people around the world."

About SQI Diagnostics

SQI Diagnostics is the life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit www.sqidiagnostics.com.

Sales and Marketing Contact:

Vice President, Global Commercial Operations
Russ Peloquin
913.484.9022
rpeloquin@sqidiagnostics.com

SQI Investor Relations Contact:

Interim Chief Executive Officer
Eric Brouwer, PhD
416.674.9500 ext. 242
ebrouwer@sqidiagnostics.com

View original content:http://www.prnewswire.com/news-releases/one-hour-coronavirus-triage-test-developed-by-sqi-diagnostics-to-receive-funding-from-university-health-network-301028568.html

SOURCE SQI Diagnostics Inc.